Phase 2Completed
Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly
Effect of Mammalian Target of Rapamycin Inhibition and Other Metabolism Modulating Interventions on the Elderly: Immune, Cognitive, and Functional Consequences
- Sponsor
- The University of Texas Health Science Center at San Antonio (Academic or other)
- Enrolment
- 34 enrolled
- Conditions
- Aging
- Interventions
- Rapamycin; Placebo; Rapamycin
- Ages
- older adults
- Registry
- NCT02874924
From the registry
The ability to mount an effective immune response declines with age, leaving the elderly increasingly susceptible to infectious diseases and cancer. Rapamycin, an FDA approved drug to prevent transplant rejection, increases the lifespan and healthspan of mice and ameliorates age-related declines in immune responsiveness, cancer survival, and cognition in laboratory animals. Investigators are conducting a translational trial to test whether rapamycin also improves life functions in humans focusing on elderly persons (aged 70-95).
Primary outcomes
- Immunological Responses